» Articles » PMID: 23292238

Surviving the Cure: Long Term Followup of Hematopoietic Cell Transplant Recipients

Overview
Specialty General Surgery
Date 2013 Jan 8
PMID 23292238
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant survivors. However, long-term survival is challenged by late relapse, late complications and late non-relapse mortality, and HCT survivors need continued lifelong surveillance for screening, early detection and timely treatment of late complications such as secondary cancers, late infections and organ toxicity. Guidelines for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT were updated and published in 2012. However, several barriers to the care of HCT survivors and routine utilization of these guidelines in clinical practice exist. Examples include paucity of and challenges to conducting prospective randomized trials for screening and prevention of late complications, lack of resources to manage late effects at the level of transplant centers and community health care providers, and inadequate tools to facilitate care and followup of HCT survivors. We summarize the long-term followup guidelines in this review, discuss ways that providers can integrate and utilize them for the care of their patients, and identify areas for research that can inform and increase the utilization of screening and prevention guidelines in clinical practice.

Citing Articles

Prehabilitation to improve function after autologous stem cell transplantation: A pilot randomized controlled trial (PIRATE).

Dennett A, Porter J, Ting S, Taylor N Support Care Cancer. 2025; 33(3):164.

PMID: 39920425 PMC: 11805779. DOI: 10.1007/s00520-025-09179-1.


International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Bone Marrow Transplant. 2024; 59(6):717-741.

PMID: 38413823 PMC: 11809468. DOI: 10.1038/s41409-023-02190-2.


International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Transplant Cell Ther. 2024; 30(4):349-385.

PMID: 38413247 PMC: 11181337. DOI: 10.1016/j.jtct.2023.12.001.


Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors.

Gronvold B, Ali M, Myklebust T, Lenartova A, Remberger M, Abrahamsen I EJHaem. 2024; 5(1):117-124.

PMID: 38406518 PMC: 10887237. DOI: 10.1002/jha2.842.


Effects of pulmonary rehabilitation in hematopoietic stem cell transplantation recipients: a randomized controlled study.

Bayram S, Bargi G, Celik Z, Bosnak Guclu M Support Care Cancer. 2023; 32(1):72.

PMID: 38158450 DOI: 10.1007/s00520-023-08236-x.